Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 57

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 57
---
 |     |                                            | 625,000 |     |       | 312,500 |     |                 | 33,598 |     |       |   971,098 |
| Jennifer Jarrett               |     |                   | 1,250,000 |     |       | 312,500 |     |                 | 55,367 |     |                        |   904,002 |     |       | 2,521,869 |     |                                            | 625,000 |     |       | 312,500 |     |                 | 27,683 |     |       |   965,183 |
| Dimitry Nuyten, M.D., Ph.D.(2) |     |                   | 1,170,000 |     |       | 263,250 |     |                 | 62,303 |     |                        |   882,233 |     |       | 2,377,786 |     |                                            | 585,000 |     |       | 263,250 |     |                 | 31,151 |     |       |   879,401 |

(1) The value of the equity acceleration would be equal to the shares multiplied by (i) in the case of options, the excess of the then current stock price over the exercise price of the options and (ii) in the case of RSUs, the then current stock price. For the purposes of this table, we have calculated the value of the acceleration using a stock price of $14.89, the closing sale price per share of our common stock on December 31, 2024, the last business day of our last fiscal year.

(2) Dr. Nuyten’s employment with us was involuntarily terminated on January 31, 2025. In exchange for a release of claims, pursuant to our severance program, we paid Dr. Nuyten a lump sum of $585,000, which was 12 months of his base salary and a lump sum of $250,000 in lieu of his 2024 bonus and will make payments for COBRA healthcare premiums for a total 12 months from the date of his termination.

Pursuant to the severance program approved by the Compensation Committee, in the event that a named executive officer is terminated without cause, the named executive officers would be entitled to received: (a) a cash lump-sum payment equal to 12 months (the "Severance Period") of the